Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 159

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Increased MAP kinase activity in Alzheimer's and Down syndrome but not in schizophrenia human brain

Open access
. Swatton, Jane E, Sellers, Lynda A., Faull, Richard L.M., Holland, Anthony, Iritani, Shuji, Bahn, Sabine·2004·European Journal of Neuroscience

Abstract

Introduction: Abnormal phosphorylation of tau is a feature of Alzheimer's disease (AD), which develops prematurely in Down syndrome (DS) patients. Cognitive impairment is also recognized as a clinical characteristic of schizophrenia, which does not appear to be associated with tau‐aggregate formation. Several kinases can phosphorylate tau in cell‐free assays. Here we show increased activity of mitogen‐activated protein kinases (MAPKs) (including ERK1/2, SAPKs and p38) in post mortem AD and DS brains, which could not be accounted for by expression changes. In contrast, glycogen synthase kinase‐3 activity (GSK‐3αβ) was reduced significantly. Examination of tau in AD and DS using antibodies selective for MAPK phosphorylation sites showed increased immunoreactivity. In addition, phosphorylation of S 199, reportedly a selective substrate for cyclin‐dependent kinase‐5 (cdk5) or GSK‐3αβ was only observed in AD samples, which showed a concomitant increase in the expression of p25, the enhancing cofactor for cdk5 activity. However, in schizophrenia brain, MAPK‐phosphorylated tau was unchanged compared to matched controls, despite similar expression levels to those in AD. The activities of the MAPKs and GSK‐3αβ were also unchanged. These data demonstrate that in AD and DS, enhanced MAPK activity, which has an established role in regulating neuronal plasticity and survival, can account for irregular tau phosphorylation, and that the molecular processes involved in these neurodegenerative disorders are distinct from those in schizophrenia. These data also question the significance of GSK‐3αβ, as much previous work carried out in vitro has placed this kinase as a favoured candidate for involvement in the pathological phosphorylation of tau.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.0953-816x.2004.03365.x

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 8 references

Cited by

See all 159

Metadata

Authors
. Swatton, J. E., Sellers, L. A., Faull, R. L. M., Holland, A., Iritani, S., & Bahn, S.
Venue
European Journal of Neuroscience
Publisher
Wiley
Published
2004-05
Volume
19
Issue
10
Pages
2711-2719
ISSN
  • 0953-816X (ISSN-L)
  • 1460-9568
OpenAlex
W1998245695
Cited by
159
References
8
FWCI
5.32
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Increased MAP kinase activity in Alzheimer's and Down syndrome but not in schizophrenia human brain. https://app.cochat.ai/papers/10.1111/j.0953-816x.2004.03365.x
The paper
. Swatton, J. E., Sellers, L. A., Faull, R. L. M., Holland, A., Iritani, S., & Bahn, S. (2004). Increased MAP kinase activity in Alzheimer's and Down syndrome but not in schizophrenia human brain. European Journal of Neuroscience. https://doi.org/10.1111/j.0953-816x.2004.03365.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.